I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

2.7 million people are estimated to have diabetes in Saudi Arabia, with estimated prevalence of 16.2%.\[[@ref1]\] Fear of hypoglycaemia and gain in body weight act as barriers for initiation of insulin therapy.\[[@ref2]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref3]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref4]\] This short communication presents the results for patients enrolled from Central Saudi Arabia.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 2819 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients started on or switched to insulin detemir (41.0%). Other groups were biphasic insulin aspart (1100), Basal plus insulin aspart (*n* = 314), insulin aspart (*n* = 34) and other insulin combinations (*n* = 170). After 24 weeks of treatment, overall hypoglycaemic events reduced from 13.0 events/patient-year to 2.1 events/patient-year in insulin user group and from 1.4 events/patient-year to 0.7 events/patient-year in insulin naive group. The hypoglycaemia incidence in insulin naive group at 24 weeks was lower than that observed in insulin users at baseline. SADRs including major hypoglycaemic events did not occur in any of the study patients. A decrease in body weight was noted at the end of the study. Blood pressure decreased and lipid profile improved at week 24 in the complete cohort \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall demographic data
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###### 

Overall safety data

![](IJEM-17-445-g002)

###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in the total cohort. More than one third of patients achieved HbA~1~c \< 7.0% at week 24 \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data
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Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 1100 patients started on biphasic insulin aspart ± OGLD, of which 605 (55%) were insulin naïve and 495 (45%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 0.8 events/patient-year to 0.7 events/patient-year in insulin naïve group and from 5.5 events/patient-year to 1.0 events/patient-year in insulin users group. Body weight decreased in insulin naïve group at the end of the study \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data
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Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort 314 patients started on basal + insulin aspart ± OGLD, of which 103 (32.8%) were insulin naïve and 211 (67.2%) were insulin users. After 24 weeks of starting or switching to basal + insulin aspart, hypoglycaemic events reduced from 4.0 events/patient-year to 2.3 events/patient-year in insulin naïve group and from 22.6 events/patient-year to 3.7 events/patient-year in insulin users group. Body weight decreased at the end of 24 weeks \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data
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Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 1156 patients who started on insulin detemir ± OGLD, of which 905 (78.2%) were insulin naïve and 251 (21.8%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemic events reduced from 1.5 events/patient-year to 0.5 events/patient-year in insulin naïve group and from 14.9 events/patient-year to 2.0 events/patient-year in insulin users group. Body weight decreased at the end of 24 weeks \[Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data
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Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 34 patients who started on insulin aspart ± OGLD, of which 28 (82.3%) were insulin naïve and 6 (17.7%) were insulin users. After 24 weeks of starting or switching to insulin aspart, hypoglycaemic events reduced from 23.8 events/patient-year to 0.0 events/patient-year in insulin user group, while hypoglycaemic events remained nil similar to that of baseline in insulin naive group \[Tables [14](#T14){ref-type="table"} and [15](#T15){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 16](#T16){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug efficacy data
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C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues (Biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. A small weight reduction was noted for all regimens except for insulin aspart group. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Central Saudi Arabia.
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